Advertisement
IQV or RVTY or TMO
Which Stock Would AI Choose? IQVIA (IQV) vs. Revvity (RVTY) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- IQVIA (IQV), Revvity (RVTY), and Thermo Fisher Scientific (TMO) operate in overlapping life sciences and healthcare services sectors but differ in business models, with IQVIA focused on clinical research and data analytics, Revvity on life science tools and diagnostics, and Thermo Fisher Scientific on broader instrumentation and lab solutions.
- Year-to-date through mid-July 2026, RVTY posted stronger returns around 14% compared to IQV near 9%, while TMO showed recovery momentum amid sector rotation.
- IQV faces near-term catalyst with second-quarter 2026 earnings scheduled for July 28, supported by a robust backlog and prior raised earnings-per-share guidance.
- RVTY delivered an earnings-per-share beat in its first-quarter 2026 report despite a slight revenue shortfall, contributing to mixed short-term price action.
- TMO benefited from signs of stabilizing lab spending and biotech funding, with notable weekly gains observed in prior months.
- Relative positioning reflects trade-offs in growth drivers, with each stock showing varying sensitivity to healthcare spending trends and market sentiment in recent weeks.
Introduction
Investors and traders seeking exposure to the life sciences and healthcare sectors often evaluate IQVIA (IQV), Revvity (RVTY), and Thermo Fisher Scientific (TMO) together due to their interconnected roles in clinical development, diagnostics, and laboratory infrastructure. These companies provide complementary services and products that support pharmaceutical research, testing, and commercialization. The comparison is particularly relevant for those monitoring sector rotation, earnings momentum, and relative valuation in a market environment influenced by biotech funding and healthcare utilization trends. This analysis highlights observable performance metrics, business positioning, and recent developments to inform a balanced assessment of their market standing.
IQV Overview and Recent Performance
IQVIA Holdings Inc. (IQV) delivers clinical research services, commercial insights, and healthcare intelligence primarily to life sciences and healthcare clients. In recent market activity, the stock has shown resilience amid broader sector movements, with year-to-date returns approaching 9% through mid-July 2026. Positive sentiment has been supported by a strong backlog and an upward revision to adjusted earnings-per-share outlook announced in late June. The company is scheduled to report second-quarter 2026 results on July 28, which market participants are watching for further confirmation of organic growth trends. Recent weeks have featured analyst upgrades and focus on the firm’s data analytics capabilities as a differentiator in clinical development efficiency.
RVTY Overview and Recent Performance
Revvity Inc. (RVTY) provides life science tools, reagents, and diagnostics solutions across research and applied markets. Through mid-July 2026, the stock recorded year-to-date gains near 14%, outpacing some peers in the period. Following first-quarter 2026 results released in early May, which featured an earnings-per-share beat alongside a modest revenue shortfall, price action remained mixed with short-term declines noted in subsequent weeks. Recent market activity reflects ongoing evaluation of demand for its portfolio amid fluctuating research spending patterns. The company continues to emphasize strategic portfolio adjustments to align with evolving customer needs in diagnostics and life sciences applications.
TMO Overview and Recent Performance
Thermo Fisher Scientific Inc. (TMO) offers a wide range of scientific instruments, reagents, and laboratory services supporting research, diagnostics, and biopharma production. In recent market activity, the stock demonstrated recovery momentum, including notable weekly gains observed around late May amid signs of improving lab spending and biotech funding conditions. Year-to-date performance has aligned with sector peers, with emphasis on its scale and diversified exposure to instrumentation and services. Recent weeks have highlighted comparisons with other life sciences tools providers as investors assess stabilization in customer capital expenditure trends.
Trending AI Robots
Tickeron maintains a curated selection of AI trading bots on its Trending AI Robots page. The platform offers hundreds of AI Trading Bots capable of trading thousands of different tickers, yet only those demonstrating the strongest alignment with prevailing market conditions receive placement in this trending section. Available bots span a range of trading styles, strategies, timeframes, performance metrics, and ticker sets, with historical statistics varying widely across the library. Users can review detailed performance data and suitability indicators directly on the page to identify options matching specific objectives.
Head-to-Head Comparison
IQVIA (IQV) centers on outsourced clinical research and data services, creating exposure to pharmaceutical development pipelines and regulatory timelines, whereas Revvity (RVTY) emphasizes specialized tools and diagnostics with sensitivity to research budgets. Thermo Fisher Scientific (TMO) offers broader instrumentation and end-to-end lab solutions, providing scale advantages but greater correlation to capital spending cycles. Recent momentum has favored RVTY on a year-to-date basis, while IQV benefits from a visible earnings catalyst and TMO from sector recovery signals. Risk factors include healthcare policy changes and funding volatility for all three, though business model differences create distinct valuation sensitivities: service-oriented exposure for IQV, product mix for RVTY, and hardware/services balance for TMO. Market sentiment in recent weeks has reflected rotation toward companies with clear backlog visibility or spending stabilization.
Tickeron AI Verdict
Based on observable trend consistency, backlog strength, and relative positioning ahead of earnings, Tickeron’s AI would currently assign a modestly higher probability of favorable near-term momentum to IQV among the three, while noting that RVTY and TMO present competitive trade-offs depending on sector spending recovery breadth. All assessments remain probabilistic and subject to evolving market data.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IQV’s FA Score shows that 0 FA rating(s) are green whileRVTY’s FA Score has 2 green FA rating(s), and TMO’s FA Score reflects 1 green FA rating(s).
- IQV’s FA Score: 0 green, 5 red.
- RVTY’s FA Score: 2 green, 3 red.
- TMO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IQV’s TA Score shows that 6 TA indicator(s) are bullish while RVTY’s TA Score has 4 bullish TA indicator(s), and TMO’s TA Score reflects 6 bullish TA indicator(s).
- IQV’s TA Score: 6 bullish, 3 bearish.
- RVTY’s TA Score: 4 bullish, 5 bearish.
- TMO’s TA Score: 6 bullish, 4 bearish.
Price Growth
IQV (@Medical Specialties) experienced а +0.87% price change this week, while RVTY (@Medical Specialties) price change was +0.29% , and TMO (@Medical Specialties) price fluctuated +6.72% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.55%. For the same industry, the average monthly price growth was +2.80%, and the average quarterly price growth was +1.12%.
Reported Earning Dates
IQV is expected to report earnings on Jul 28, 2026.
RVTY is expected to report earnings on Aug 04, 2026.
TMO is expected to report earnings on Oct 28, 2026.
Industries' Descriptions
@Medical Specialties (-1.55% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| IQV | RVTY | TMO | |
| Capitalization | 34.7B | 12.3B | 211B |
| EBITDA | 3.52B | 773M | 11.7B |
| Gain YTD | -7.702 | 14.411 | -1.736 |
| P/E Ratio | 25.84 | 53.11 | 30.58 |
| Revenue | 16.6B | 2.9B | 45.2B |
| Total Cash | 2.1B | N/A | 1.12B |
| Total Debt | 16.1B | 3.35B | 43.2B |
IQV | RVTY | TMO | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 85 | 79 | 37 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 65 Fair valued | 15 Undervalued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 80 | |
SMR RATING 1..100 | 42 | 89 | 62 | |
PRICE GROWTH RATING 1..100 | 43 | 45 | 42 | |
P/E GROWTH RATING 1..100 | 62 | 28 | 37 | |
SEASONALITY SCORE 1..100 | 65 | n/a | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (12) in the Medical Specialties industry is in the same range as RVTY (15) in the Medical Specialties industry, and is somewhat better than the same rating for IQV (65) in the Servicestothe Health Industry industry. This means that TMO's stock grew similarly to RVTY’s and somewhat faster than IQV’s over the last 12 months.
TMO's Profit vs Risk Rating (80) in the Medical Specialties industry is in the same range as RVTY (100) in the Medical Specialties industry, and is in the same range as IQV (100) in the Servicestothe Health Industry industry. This means that TMO's stock grew similarly to RVTY’s and similarly to IQV’s over the last 12 months.
IQV's SMR Rating (42) in the Servicestothe Health Industry industry is in the same range as TMO (62) in the Medical Specialties industry, and is somewhat better than the same rating for RVTY (89) in the Medical Specialties industry. This means that IQV's stock grew similarly to TMO’s and somewhat faster than RVTY’s over the last 12 months.
TMO's Price Growth Rating (42) in the Medical Specialties industry is in the same range as IQV (43) in the Servicestothe Health Industry industry, and is in the same range as RVTY (45) in the Medical Specialties industry. This means that TMO's stock grew similarly to IQV’s and similarly to RVTY’s over the last 12 months.
RVTY's P/E Growth Rating (28) in the Medical Specialties industry is in the same range as TMO (37) in the Medical Specialties industry, and is somewhat better than the same rating for IQV (62) in the Servicestothe Health Industry industry. This means that RVTY's stock grew similarly to TMO’s and somewhat faster than IQV’s over the last 12 months.
| IQV | RVTY | TMO | |
|---|---|---|---|
| RSI ODDS (%) | 3 days ago 56% | 3 days ago 71% | 3 days ago 61% |
| Stochastic ODDS (%) | 3 days ago 63% | 3 days ago 78% | 3 days ago 60% |
| Momentum ODDS (%) | 3 days ago 64% | 3 days ago 71% | 3 days ago 59% |
| MACD ODDS (%) | 3 days ago 50% | 3 days ago 84% | 3 days ago 66% |
| TrendWeek ODDS (%) | 3 days ago 61% | 3 days ago 65% | 3 days ago 61% |
| TrendMonth ODDS (%) | 3 days ago 63% | 3 days ago 61% | 3 days ago 61% |
| Advances ODDS (%) | 3 days ago 60% | 4 days ago 64% | 4 days ago 61% |
| Declines ODDS (%) | 5 days ago 65% | 7 days ago 67% | 6 days ago 63% |
| BollingerBands ODDS (%) | 3 days ago 66% | 3 days ago 71% | 3 days ago 63% |
| Aroon ODDS (%) | 3 days ago 57% | 3 days ago 64% | 3 days ago 59% |
Advertisement
IQV and
Correlation & Price change
A.I.dvisor indicates that over the last year, IQV has been closely correlated with CRL. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if IQV jumps, then CRL could also see price increases.
| Ticker / NAME | Correlation To IQV | 1D Price Change % | ||
|---|---|---|---|---|
| IQV | 100% | +0.35% | ||
| CRL - IQV | 75% Closely correlated | -1.18% | ||
| TMO - IQV | 71% Closely correlated | -0.71% | ||
| MEDP - IQV | 65% Loosely correlated | -0.73% | ||
| RVTY - IQV | 64% Loosely correlated | -2.39% | ||
| A - IQV | 62% Loosely correlated | -0.84% | ||
More | ||||